Menu
/REGISTER
Montecito
Nixon Peabody
Pac Premier
Loading...
You are here:  Home  >  'Neulasta'
Latest

Amgen releases 4th quarter earnings

By   /  Thursday, January 30th, 2020  /  Biotech, Earnings, Latest news  /  Comments Off on Amgen releases 4th quarter earnings

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen earnings per share up 20 percent due to higher product sales

By   /  Thursday, July 26th, 2018  /  Central Coast Health Watch, Earnings, East Ventura County, Latest news, Tri-County Public Companies  /  Comments Off on Amgen earnings per share up 20 percent due to higher product sales

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

FDA approves biosimilar of Amgen’s Neulasta

By   /  Monday, June 4th, 2018  /  Central Coast Health Watch, East Ventura County, Latest news, Technology  /  Comments Off on FDA approves biosimilar of Amgen’s Neulasta

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen beats analysts’ revenue, earnings per share estimates

By   /  Thursday, October 27th, 2016  /  Central Coast Health Watch, Earnings, Latest news, Tri-County Public Companies  /  Comments Off on Amgen beats analysts’ revenue, earnings per share estimates

Amgen revenues increased 2 percent during the third quarter as it beat analysts’ revenue and earnings per share estimates thanks to cost-cutting measures and lower research measures. Revenues for the Thousand Oaks-based biotech giant increased from $5.72 billion during the third quarter of 2015 to $5.81 billion in 2016, which beat analyst estimates of $5.73 Read More →

Read More →
Latest

Silence is deafening when new drugs are not approved

By   /  Friday, August 5th, 2016  /  Columns, Latest news, Technology  /  Comments Off on Silence is deafening when new drugs are not approved

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen reports revenue increase in second quarter earnings

By   /  Wednesday, July 27th, 2016  /  Central Coast Health Watch, Earnings, Latest news, Tri-County Public Companies, West Ventura County  /  Comments Off on Amgen reports revenue increase in second quarter earnings

Updated on July 27 at 4 p.m.: Amgen reported a 6 percent increase in revenue and a 15 percent increase in earnings per share in its second quarter earnings released July 27. Revenues grew to $5.7 billion due to higher sales of the company’s drugs Enbrel, Prolia, Kyprolis and Xgeva, and operating income increased 15 Read More →

Read More →
Latest

FDA declines to approve Novartis biosimilar for Amgen’s Neulasta

By   /  Tuesday, July 19th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on FDA declines to approve Novartis biosimilar for Amgen’s Neulasta

The Food and Drug Administration has declined for now to approve a copycat version of Amgen’s blockbuster drug Neulasta. Reuters reported July 19 that the FDA sent a letter to Swiss pharmaceutical Novartis at the end of June saying it was declining to approve the drug for now. Neulasta, made by Thousand Oaks-based biotech giant Read More →

Read More →